Log In
Sunday 25th August 2019

NICE rejects advanced breast cancer drug

22nd March 2013

The National Institute for Health and Clinical Excellence (NICE) has decided it will not recommend the use of everolimus to treat advanced breast cancer.


NICE’s chief executive Sir Andrew Dillon said: "While the independent Appraisal Committee acknowledged that everolimus may offer a step change in treatment by restoring sensitivity of the tumour to hormone therapy, the evidence highlighted uncertainty relating to how much the treatment extends overall survival. Using the most appropriate estimates, the committee concluded that everolimus is not a cost-effective treatment option for the NHS." Baroness Delyth Morgan, chief executive of Breast Cancer Campaign, said: "The draft recommendation … will be extremely disappointing for women who could benefit from this treatment."

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2019